Last reviewed · How we verify
Sodium Tetradecyl Sulphate
At a glance
| Generic name | Sodium Tetradecyl Sulphate |
|---|---|
| Also known as | Fibrovein Solution for Injection |
| Sponsor | Hull University Teaching Hospitals NHS Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias (PHASE4)
- Pilot RCT Evaluating a One Stop Vein Clinic (NA)
- Investigation Into the Pathophysiology and Treatment of Varicose Veins (NA)
- Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations (PHASE4)
- Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding (PHASE3)
- Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia (NA)
- Laser Ablation Versus Mechanochemical Ablation Trial (PHASE4)
- Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Tetradecyl Sulphate CI brief — competitive landscape report
- Sodium Tetradecyl Sulphate updates RSS · CI watch RSS
- Hull University Teaching Hospitals NHS Trust portfolio CI